Skip to main content
padlock icon - secure page this page is secure

Open Access Human infection challenge vaccine (HIC-vac) network

Download Article:
 Download
(PDF 457.5 kb)
 
HIC-Vac is an international network of researchers working together to grow and develop human infection challenge studies, with the goal of accelerating the development of vaccines against pathogens that have a high global impact. The aim is to reduce the burden of some of the world's most crippling diseases. While new vaccines are being brought to market every year there are still some major gaps that need to be addressed. And given the decline in the efficacy of antibiotics and the rise in antimicrobial resistance, a focus on new bacterial vaccines is becoming particularly urgent. HIC-Vac provides small awards to members who have developed a high quality research proposal to carry out preliminary work for new human challenge studies, or to add value to existing studies. One specific goal is to accelerate development of vaccines that are beneficial in low and middle income countries, where preventing disease will have the biggest impact. Human challenge studies can play an important role in accelerating vaccine development by providing a proof of principle that the vaccine has efficacy in a small group of participants. This can reduce the time and cost it takes to get an indication of whether a candidate vaccine has promise and should be pursued. But the wider benefits of human challenge studies must be weighed up against the ethical acceptability of experimentally exposing people to an infection. Research ethics committees in the UK are integral in ensuring that HIC-Vac supports projects that are ethical and give robust results that justify the model.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ACCELERATING VACCINES; ANTIMICROBIAL RESISTANCE; BBSCR; CHIM; CONTROLLED HUMAN INFECTION MODEL; ETHICAL; ETHICS; GCRF NETWORKS IN VACCINE RESEARCH; HIC; HIC-VAC; HUMAN INFECTION CHALLENGE; LMICS; MRC; PATHOGENS OF HIGH GLOBAL BURDEN; REGULATORY; VACCINE DEVELOPMENT; VACCINES; VOLUNTEERS

Document Type: Research Article

Affiliations: Imperial College London, United Kingdom

Publication date: April 1, 2019

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more